Israel - hebraico - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii

Israel - hebraico - Ministry of Health

מדיסון פארמה בע"מ - מומחה - פרוצדורת רוטבלייטור

Israel - hebraico - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Israel - hebraico - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 1000 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Israel - hebraico - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Israel - hebraico - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 250 iu/vial - coagulation factor viii

Israel - hebraico - Ministry of Health

dover medical & scientific equipment ltd, israel - coagulation factor ii (human); coagulation factor ix (human- rfixfc); coagulation factor vii (human); coagulation factor x (human); protein; protein c; protein s antigen - אבקה וממס להכנת תמיסה לאינפוזיה - coagulation factor ix (human- rfixfc) 25 iu/ml; coagulation factor ii (human) 14 - 38 iu/ml; coagulation factor vii (human) 9 - 24 iu/ml; coagulation factor x (human) 18 - 30 iu/ml; protein 13 - 41 mg/ml; protein c 13 - 31 iu/ml; protein s antigen 12 - 32 iu/ml - coagulation factor ix, ii, vii and x in combination

Israel - hebraico - Ministry of Health

sanofi - aventis israel ltd - coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - coagulation factor viii 1000 iu - coagulation factor vii

Israel - hebraico - Ministry of Health

sanofi - aventis israel ltd - coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - coagulation factor viii 1500 iu - coagulation factor viii

Israel - hebraico - Ministry of Health

sanofi - aventis israel ltd - coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - coagulation factor viii 2000 iu - coagulation factor viii